ParkinD.M.: Cancer burden in the year 2000. The global picture. Eur J Cancer, 37: S4–66, 2001.
2.
SatarianoW.A.: The effect of comorbidity on 3-year survival of women with primary BC. Ann Int Med, 120: 104–110, 1994.
3.
Anonymous:Poly chemotherapy for early ca: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 352: 930, 1998.
4.
Anonymous:Tamoxifen for early ca: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 351: 1451, 1998.
5.
DeshC.E.: Should the elderly receive chemotherapy for node negative breast cancer?A cost-effectiveness analysis ex-aminig total and active life-expectancy outcomes. J Clin Oncol, 11: 777, 1993.
6.
GermanR.S.: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using dosing doses based on creatinine clearance. J Clin Oncol, 2: 1404, 1984.
7.
Giovanazzi-BannonS.: Treatment tolerance of elderly cancer patients entered into phase 2 clinical trials: an Illinois Cancer Centerstudy. J Clin One, 12: 2447, 1994.
8.
CrivellariD.: Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol, 18: 1412–1422, 2000.
9.
MussH.B.: Breast cancer in the elderly: the role of systemic adjuvant therapy, Asco, 2001.
